A new drug developed by Taipei-based Foresee Pharmaceuticals Co. to treat acute respiratory distress syndrome (ARDS) in COVID-19 patients has received the approval of an independent data monitoring committee (IDMC) in the United States.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
-
Business
Taiwan shares open lower
03/13/2026 09:09 AM -
Cross-Strait
Legislature's decision not to kick out TPP lawmaker 'regrettable': MAC
03/12/2026 10:01 PM -
Sports
Taiwan wins 3 golds on Day 1 of World Indoor Tug of War Championships
03/12/2026 09:48 PM -
Society
Taiwan raises water alert for Hsinchu, lowers nighttime supply pressure
03/12/2026 09:42 PM -
Culture
Sports stars among nominees for PTS board of directors
03/12/2026 09:09 PM